Home > Publications database > Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation. > print

001     166277
005     20240229123224.0
024 7 _ |a 10.3390/cancers12113465
|2 doi
024 7 _ |a pmid:33233777
|2 pmid
024 7 _ |a pmc:PMC7699843
|2 pmc
024 7 _ |a altmetric:94808420
|2 altmetric
037 _ _ |a DKFZ-2020-02770
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Colmenero-Repiso, Ana
|b 0
245 _ _ |a Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation.
260 _ _ |a Basel
|c 2020
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1609263237_1255
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Neuroblastoma (NB) is one of the most common pediatric cancers and presents a poor survival rate in affected children. Current pretreatment risk assessment relies on a few known molecular parameters, like the amplification of the oncogene MYCN. However, a better molecular knowledge about the aggressive progression of the disease is needed to provide new therapeutical targets and prognostic markers and to improve patients' outcomes. The human protein kinase VRK1 phosphorylates various signaling molecules and transcription factors to regulate cell cycle progression and other processes in physiological and pathological situations. Using neuroblastoma tumor expression data, tissue microarrays from fresh human samples and patient-derived xenografts (PDXs), we have determined that VRK1 kinase expression stratifies patients according to tumor aggressiveness and survival, allowing the identification of patients with worse outcome among intermediate risk. VRK1 associates with cell cycle signaling pathways in NB and its downregulation abrogates cell proliferation in vitro and in vivo. Through the analysis of ChIP-seq and methylation data from NB tumors, we show that VRK1 is a MYCN gene target, however VRK1 correlates with NB aggressiveness independently of MYCN gene amplification, synergizing with the oncogene to drive NB progression. Our study also suggests that VRK1 inhibition may constitute a novel cell-cycle-targeted strategy for anticancer therapy in neuroblastoma.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a MYCN
|2 Other
650 _ 7 |a VRK1
|2 Other
650 _ 7 |a high-risk
|2 Other
650 _ 7 |a neuroblastoma
|2 Other
650 _ 7 |a proliferation
|2 Other
650 _ 7 |a tumorigenesis
|2 Other
700 1 _ |a Gómez-Muñoz, María A
|0 0000-0002-6478-8197
|b 1
700 1 _ |a Rodríguez-Prieto, Ismael
|b 2
700 1 _ |a Amador-Álvarez, Aida
|0 0000-0001-5692-1202
|b 3
700 1 _ |a Henrich, Kai-Oliver
|0 P:(DE-He78)a579ca2567736066534409e732b31c91
|b 4
|u dkfz
700 1 _ |a Pascual-Vaca, Diego
|b 5
700 1 _ |a Okonechnikov, Konstantin
|0 P:(DE-He78)34b3639de467b2c700920d7cbc3d2110
|b 6
|u dkfz
700 1 _ |a Rivas, Eloy
|b 7
700 1 _ |a Westermann, Frank
|0 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
|b 8
|u dkfz
700 1 _ |a Pardal, Ricardo
|0 0000-0003-1085-0714
|b 9
700 1 _ |a Vega, Francisco M
|0 0000-0002-9015-864X
|b 10
773 _ _ |a 10.3390/cancers12113465
|g Vol. 12, no. 11, p. 3465 -
|0 PERI:(DE-600)2527080-1
|n 11
|p 3465
|t Cancers
|v 12
|y 2020
|x 2072-6694
909 C O |o oai:inrepo02.dkfz.de:166277
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a579ca2567736066534409e732b31c91
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)34b3639de467b2c700920d7cbc3d2110
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2020
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2018
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-09-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2020-09-11
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-09-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-09-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-09-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2018
|d 2020-09-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-11
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)B087-20160331
|k B087
|l B087 Neuroblastom Genomik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B087-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21